ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
- Previous Close
1.4220 - Open
1.4000 - Bid 1.3800 x --
- Ask 1.4080 x --
- Day's Range
1.3760 - 1.4580 - 52 Week Range
0.7130 - 5.9700 - Volume
80,573 - Avg. Volume
148,041 - Market Cap (intraday)
72.378M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.7800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.00
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase III clinical trial. It also develops influenza, breast cancer, and malaria vaccines. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. Further, it sells ExpreS2 test kits and reagents for application as research tools or diagnostics. It has a collaboration agreement with Evaxion Biotech A/S for the development of a novel cytomegalovirus (CMV) vaccine candidate. The company operates an online store. ExpreS2ion Biotech Holding AB (publ) was incorporated in 2015 is based in Helsingborg, Sweden.
www.expres2ionbio.comRecent News: EXPRS2.ST
Performance Overview: EXPRS2.ST
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EXPRS2.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EXPRS2.ST
Valuation Measures
Market Cap
72.38M
Enterprise Value
16.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.27
Price/Book (mrq)
1.11
Enterprise Value/Revenue
2.34
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-59.55%
Return on Equity (ttm)
-125.26%
Revenue (ttm)
7.77M
Net Income Avi to Common (ttm)
-82.53M
Diluted EPS (ttm)
-1.7800
Balance Sheet and Cash Flow
Total Cash (mrq)
60.2M
Total Debt/Equity (mrq)
0.56%
Levered Free Cash Flow (ttm)
-33.94M
Research Analysis: EXPRS2.ST
Company Insights: EXPRS2.ST
EXPRS2.ST does not have Company Insights